{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:06:46Z","timestamp":1790910406656,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2003,4,1]]},"abstract":"<jats:p> Purpose: R115777 is a selective nonpeptidomimetic inhibitor of farnesyltransferase (FTase), one of several enzymes responsible for posttranslational modification that is required for the function of p21<jats:sup>ras<\/jats:sup> and other proteins. Given that RAS mutations are nearly universal in pancreatic cancer and R115777 demonstrated preclinical activity against pancreatic cell lines and xenografts, this phase II study was undertaken to determine its clinical activity and effect on target proteins in patients with measurable metastatic pancreatic adenocarcinoma. <\/jats:p><jats:p> Patients and Methods: Twenty patients who had not received prior therapy for metastatic disease were treated with 300 mg of R115777 orally every 12 hours for 21 of 28 days. Inhibition of FTase activity in peripheral-blood mononuclear cells was measured using a lamin B C-terminus peptide as substrate. Western blot analysis was performed to monitor farnesylation status of the chaperone protein HDJ-2. <\/jats:p><jats:p> Results: No objective responses were seen. Median time to progression was 4.9 weeks, and median survival time was 19.7 weeks. The estimated 6-month survival rate was 25%, with no patients progression-free at 6 months. Grade 3\/4 toxicities were liver enzyme elevation, anemia, neutropenia, thrombocytopenia, fatigue, nausea\/vomiting, rash, and anorexia. FTase activity (mean \u00b1 SD) decreased by 49.8% \u00b1 9.8% 4 hours after treatment on day 1 and 36.1% \u00b1 24.8% before treatment on day 15. HDJ-2 farnesylation (mean \u00b1 SD) decreased by 33.4% \u00b1 19.8% on day 15. <\/jats:p><jats:p> Conclusion: Although treatment with R115777 resulted in partial inhibition of FTase activity in mononuclear cells, it did not exhibit single-agent antitumor activity in patients with previously untreated metastatic pancreatic cancer. <\/jats:p>","DOI":"10.1200\/jco.2003.08.040","type":"journal-article","created":{"date-parts":[[2003,3,27]],"date-time":"2003-03-27T19:03:23Z","timestamp":1048791803000},"page":"1301-1306","source":"Crossref","is-referenced-by-count":146,"title":["Phase II and Pharmacodynamic Study of the Farnesyltransferase Inhibitor R115777 as Initial Therapy in Patients With Metastatic Pancreatic Adenocarcinoma"],"prefix":"10.1200","volume":"21","author":[{"given":"Steven J.","family":"Cohen","sequence":"first","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"Ho","sequence":"additional","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulabha","family":"Ranganathan","sequence":"additional","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Abbruzzese","sequence":"additional","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Katherine","family":"Alpaugh","sequence":"additional","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Beard","sequence":"additional","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Lewis","sequence":"additional","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Rogatko","sequence":"additional","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Perez-Ruixo","sequence":"additional","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Thistle","sequence":"additional","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Verhaeghe","sequence":"additional","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis M.","family":"Weiner","sequence":"additional","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Wright","sequence":"additional","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R.","family":"Hudes","sequence":"additional","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal J.","family":"Meropol","sequence":"additional","affiliation":[{"name":"From the Fox Chase Cancer Center, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer Therapy Evaluation Program, Bethesda, MD; and Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.52.1.23"},{"key":"R2","unstructured":"Schnall SF, Macdonald JS: Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23:220,1996\u2013228,"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199709000-00004"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-000-0065-2"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2403"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.149"},{"key":"R7","unstructured":"End DW, Smets G, Todd AV, et al: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61:131,2001\u2013137,"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910430614"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204146"},{"key":"R10","unstructured":"Hudes GR, Schol J, Baab J, et al: Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule. Proc Am Soc Clin Oncol 18:156a,1999,  (abstr 601)"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Rogatko A, Litwin S: Phase II studies: Which is worse, false positive or false negative? J Natl Cancer Inst 88:462,1996,","DOI":"10.1093\/jnci\/88.7.462"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:547,1958\u2013581,","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R15","unstructured":"Van Cutsem E, Karasek P, Oettle H, et al: Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 21:130a,2002,  (abstr 517)"},{"key":"R16","unstructured":"Macdonald JS, Chansky K, Whitehead R, et al: A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest Oncology Group (SWOG) study. Proc Am Soc Clin Oncol 21:138a,2002,  (abstr 548)"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Adjei AA, Mauer A, Marks R, et al: A phase II study of the farnesyltransferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 21:290a,2002,  (abstr 1156)","DOI":"10.1200\/JCO.2003.09.075"},{"key":"R18","unstructured":"Haas N, Peereboom D, Ranganathan S, et al: Phase II trial of R115777, an inhibitor of farnesyltransferase, in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 21:181a,2002,  (abstr 721)"},{"key":"R19","unstructured":"Cunningham D, de Gramont A, Scheithauer W, et al: Randomized double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra) in advanced refractory colorectal cancer. Proc Am Soc Clin Oncol 21:126a,2002,  (abstr 502)"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3361"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Johnston SRD, Hickish T, Houston S, et al: Efficacy and tolerability of two drug regimens of R115777 (Zarnestra), a farnesyl protein transferase inhibitor in patients with advanced breast cancer. Proc Am Soc Clin Oncol 21:35a,2002,  (abstr 138)","DOI":"10.1200\/JCO.2003.10.064"},{"key":"R22","unstructured":"Gotlib J, Dugan K, Katamneni U, et al: Phase I\/II study of farnesyltransferase inhibitor R115777 (Zarnestra) in patients with myeloproliferative disorders (MPDs): Preliminary results. Proc Am Soc Clin Oncol 21:4a,2002,  (abstr 14)"},{"key":"R23","unstructured":"Sepp-Lorenzino L, Ma Z, Rands E, et al: A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55:5302,1995\u20135309,"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201296"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.4.927"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.116"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(01)00005-3"},{"key":"R28","unstructured":"Cohen SJ, Meropol NJ: Drug development in pancreatic cancer: Finally biology begets therapy. Int J Gastrointest Cancer  (in press)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2003.08.040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:36:24Z","timestamp":1653510984000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2003.08.040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,1]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,4,1]]}},"alternative-id":["10.1200\/JCO.2003.08.040"],"URL":"https:\/\/doi.org\/10.1200\/jco.2003.08.040","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4,1]]}}}